Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial-Reference-Cited by-同舟云学术

Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial

Published:2024-04 Issue:12 Volume:42 Page:3009-3017
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Nurdin Asrawati^ORCID,Movieta Nency Yetty,Maddeppungeng Martira^ORCID,Sekartini Rini,Mulia Sari Rini,Surachman Fikrianti^ORCID,Fitry Yani Finny,Raveinal ,Anggrainy Fenty,Hafiz Al^ORCID,Linosefa ,Machmud Rizanda,Awaliyah Deza Putri,Rujiana Vovinda^ORCID,Bella Rahimi Martga,Farhanah Nur^ORCID,Gundi Pramudo Setyo,Hapsari Rebriarina^ORCID,Tri Anantyo Dimas,Mulyono ,Mahati Endang^ORCID,Maharani Nani^ORCID,Darma Sidrah^ORCID,Husni Esa Darussalam Andi,Shakinah Sharifah,Nasrum Massi Muhammad,Soedjatmiko

Funder

Bio Farma Persero PT

Publisher

Elsevier BV

Reference36 articles.

1. World Health Organization Indonesia. Coronavirus disease 2019 (COVID-19) situation report – 53. 2020. Accessed: Apr. 30, 2021. [Online]. Available: https://www.who.int/publications/m/item/situation-report---53.

2. Hotezid PJ, Bottazziid ME. Developing a low-cost and accessible COVID-19 vaccine for global health; 2020, doi: 10.1371/journal.pntd.0008548.

3. Fujiwara Y, Raine J. ICMRA COVID-19 vaccine development: future steps workshop. Accessed: Mar. 24, 2022. [Online]. Available: https://www.icmra.info/drupal/en/covid-19/24june2021.

4. World Health Organization. Considerations for the assessment of COVID-19 vaccines for listing by WHO (version 30 March 2022), Mar. 30, 2022.

5. Ministry of Health Republic of Indonesia, “Hasil sero survey : 86,6% penduduk Indonesia memiliki antibodi terhadap COVID-19,” 2022. Accessed: Mar. 24, 2022. [Online]. Available: https://sehatnegeriku.kemkes.go.id/baca/rilis-media/penelitian-dan-pengembangan-kesehatan/20220318/3139545/hasil-sero-survey-866-penduduk-indonesia-memiliki-antibodi-terhadap-covid-19/.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents;Vaccines;2024-08-22

2. Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Booster Dose against COVID-19 in Indonesian Adults;Vaccines;2024-05-14